Invizyne Technologies, a pre-revenue biotechnology company, reported a net loss of $1.66 million for the three months ended September 30, 2024, and a net loss of $4.03 million for the nine months ended September 30, 2024. The company's operating costs increased significantly, with general and administrative costs rising to $888,239 for the quarter and $2.71 million for the nine months, and research and development costs, net of grants, reaching $723,487 for the quarter and $1.24 million for the nine months. The company completed its IPO on November 13, 2024, raising approximately $14.3 million in net proceeds. The company plans to use the IPO proceeds for expansion of production capabilities, staffing, R&D, and repayment of intercompany loans. As of September 30, 2024, the company had cash and cash equivalents of $233,935 and a working capital deficit of $4.38 million. The company has received grants from the Department of Energy and the NIH, with the Department of Energy contributing 64% and the NIH contributing 36% of grant reimbursements for the nine months ended September 30, 2024. The company has a license agreement with The Regents of the University of California, requiring milestone payments upon reaching certain sales thresholds. The company has two operating leases for office space, with a weighted average remaining lease term of 5.20 years and a weighted average discount rate of 7.88%.